Details for: PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Company: SANDOZ CANADA INCORPORATED
DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
---|---|---|---|---|---|
02299623 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM) | 2 G / VIAL; 0.25 G / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
02299631 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM) | 3 G / VIAL; 0.375 G / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
02299658 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM) | 4 G / VIAL; 0.5 G / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
02330547 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM) | 12 G / VIAL; 1.5 G / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
02521539 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM) | 36 G / VIAL; 4.5 G / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
Summary Reports
Summary Safety Review - Piperacillin Containing Products (alone or in combination with tazobactam) - Assessing the Potential Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Beta-lactam antibiotics - Assessing the potential risk of severe skin side effects
Summary Safety Review - Beta-lactam antibiotics - Assessing the potential risk of severe skin side effects
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.